Recently, studies showed that disease-modifying therapies(DMTs) could balance the dysregulation of miRNAs in the immune cells of patients with relapsing-remitting MS (RRMS).Interferon-beta (IFN-β) has emerged as one of the most common drugs for the treatment of RR-MS patients. The gene discussed is IFNB1; the disease is myeloid sarcoma.